KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Leases (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 11 years of Leases data on record, last reported at $576.7 million in Q4 2025.

  • For Q4 2025, Leases rose 165.27% year-over-year to $576.7 million; the TTM value through Dec 2025 reached $576.7 million, up 165.27%, while the annual FY2025 figure was $576.7 million, 165.27% up from the prior year.
  • Leases reached $576.7 million in Q4 2025 per REGN's latest filing, up from $217.4 million in the prior quarter.
  • Across five years, Leases topped out at $620.3 million in Q4 2022 and bottomed at $217.4 million in Q4 2024.
  • Average Leases over 4 years is $505.0 million, with a median of $591.2 million recorded in 2023.
  • Peak YoY movement for Leases: plummeted 64.11% in 2024, then surged 165.27% in 2025.
  • A 4-year view of Leases shows it stood at $620.3 million in 2022, then fell by 2.35% to $605.7 million in 2023, then tumbled by 64.11% to $217.4 million in 2024, then soared by 165.27% to $576.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Leases were $576.7 million in Q4 2025, $217.4 million in Q4 2024, and $605.7 million in Q4 2023.